S100A9 and systemic lupus erythematosus: Based on studies suggesting a role for S100a9 in MDSC-driven immunosuppression in cancer (25), we hypothesized that MDSCs utilized S100a9 to inhibit immune activation and disease progression in NZBWF1 lupus-prone males.